Otamixaban
Otamixaban is an experimental injectable anticoagulant direct [factor Xa inhibitor] that was investigated for the treatment for acute [coronary syndrome]. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase [III clinical trial].